Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.55 |
|---|---|
| 52-week range | $0.90 - $4.84 |
| 50-day moving average | $1.74 |
| 200-day moving average | $1.58 |
| Wall St. target price | $12.53 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.58 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.554 from 2023-03-20
| 1 week (2023-03-14) | 8.67% |
|---|---|
| 1 month (2023-02-22) | -10.17% |
| 3 months (2022-12-22) | 26.34% |
| 6 months (2022-09-22) | 13.43% |
| 1 year (2022-03-22) | -65.23% |
|---|---|
| 2 years (2021-03-22) | -91.72% |
| 3 years (2020-03-18) | N/A |
| 5 years (2018-03-18) | N/A |
| Revenue TTM | $12.7 million |
|---|---|
| Gross profit TTM | $10.2 million |
| Return on assets TTM | -26.15% |
| Return on equity TTM | -55.96% |
| Profit margin | 0% |
| Book value | $2.60 |
| Market capitalisation | $69.2 million |
TTM: trailing 12 months
We're not expecting Adagene to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Adagene's shares have ranged in value from as little as $0.9 up to $4.842. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adagene's is 0.0692. This would suggest that Adagene's shares are less volatile than average (for this exchange).
To put Adagene's beta into context you can compare it against those of similar companies.
Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. .
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.